Prosecution Insights
Last updated: October 02, 2026

Examiner: WOOLWINE, SAMUEL C

Tech Center 1600 • Art Units: 1634 1637 1651 1656 1681 1683

This examiner grants 61% of resolved cases

Analysis

Samuel C. Woolwine has resolved 866 cases in Art Unit 1634. The allowance rate is 61.0 percent, which is moderate for Tech Center 1600. The median days to allowance is 1311, reflecting a lengthy prosecution process. This 1311-day figure helps practitioners set realistic expectations for the time required to reach a grant.

The interview lift is 20.4 percent. This indicates that interviews are an effective way to improve the chances of an allowance. Given the 61.0 percent baseline and the 1311-day median, an interview is a strategic choice to move cases toward a successful conclusion. Practitioners should consider direct verbal communication to leverage the 20.4 percent lift and overcome any rejections.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

61.0%
Allow Rate
+1.0% vs TC avg
905
Total Applications
+20.4%
Interview Lift
1311
Avg Prosecution Days
Based on 866 resolved cases, 2023–2026

Rejection Statute Breakdown

6.1%
§101 Eligibility
14.2%
§102 Novelty
37.1%
§103 Obviousness
30.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18794356 METHODS FOR THE DIAGNOSIS OF BACTERIAL VAGINOSIS Final Rejection Quest Diagnostics Investments LLC
18643905 Monocarboxylic Acid Transporter 4 as a Biomarker for Hypoxia Driven Tumor Growth and Treatment Non-Final OA NantBio, Inc.
17516215 METHOD OF OPTIMIZING EFFICACY OF THERAPEUTIC AGENT Non-Final OA Abbott Diabetes Care Inc.
18261812 COMPOSITIONS, KITS AND METHODS FOR DIRECT AMPLIFICATION FROM CRUDE BIOLOGICAL SAMPLES Final Rejection LIFE TECHNOLOGIES CORPORATION
18658702 COVALENTLY LINKED BRANCHED DNA STRUCTURES AND USES THEREOF Non-Final OA 10x Genomics, Inc.
18438896 INCREASING CAPTURE EFFICIENCY OF SPATIAL ASSAYS Non-Final OA 10x Genomics, Inc.
18236783 SINGLE CELL GLYCAN PROFILING Non-Final OA 10X GENOMICS, INC.
18705695 COMPOSITIONS AND METHODS FOR DETECTING OROPHARYNGEAL CANCER Non-Final OA Mayo Foundation for Medical Education and Research
17825878 Methods and Compositions Employing Blocked Primers Non-Final OA Takara Bio USA, Inc.
17788781 GUIDED EXCISION-TRANSPOSITION SYSTEMS Non-Final OA MASSACHUSETTS INSTITUTE OF TECHNOLOGY
18723184 SUPPRESSION OF NON-SPECIFIC SIGNALS BY EXONUCLEASES IN FISH EXPERIMENT Non-Final OA CALIFORNIA INSTITUTE OF TECHNOLOGY
18433250 Methods for Detecting Target Analytes Non-Final OA California Institute of Technology
17866240 STOICHIOMETRIC EXPRESSION OF MESSENGER POLYCISTRONS Final Rejection California Institute of Technology
18647611 MAGNET ASSEMBLY TO PREVENT EXTRACTION PARTICLE CARRYOVER Non-Final OA BECTON, DICKINSON AND COMPANY
18547495 METHODS FOR PROGNOSING, DIAGNOSING, AND TREATING COLORECTAL CANCER Final Rejection BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17758415 TRANSPOSITION-BASED DIAGNOSTICS METHODS AND DEVICES Non-Final OA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
18714695 ASSAY Non-Final OA CAMBRIDGE ENTERPRISE LIMITED
17054233 METHOD FOR DETECTING GUT MICROORGANISM IN A SAMPLE USING NORMAL GUT FLORA AS INTERNAL CONTROL Non-Final OA SEEGENE, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month